98%
921
2 minutes
20
Purpose: Few studies have examined whether bioengineering can improve fecal incontinence. This study designed to determine whether injection of porous polycaprolactone beads containing autologous myoblasts improves sphincter function in a dog model of fecal incontinence.
Methods: The anal sphincter of dogs was injured and the dogs were observed without and with (n = 5) the injection of porous polycaprolactone beads containing autologous myoblasts into the site of injury. Autologous myoblasts purified from the gastrocnemius muscles were transferred to the beads. Compound muscle action potentials (CMAP) of the pudendal nerve, anal sphincter pressure, and histopathology were determined 3 months after treatment.
Results: The amplitudes of the CMAP in the injured sphincter were significantly lower than those measured before injury (1.22 mV vs. 3.00 mV, P = 0.04). The amplitudes were not different between dogs with and without the injection of autologous myoblast beads (P = 0.49). Resting and squeezing pressures were higher in dogs treated with autologous myoblast beads (2.00 mmHg vs. 1.80 mmHg; 6.13 mmHg vs. 4.02 mmHg), although these differences were not significant in analyses of covariance adjusted for baseline values. The injection site was stained for smooth muscle actin, but showed evidence of foreign body inflammatory reactions.
Conclusion: This was the first study to examine whether bioengineering could improve fecal incontinence. Although the results did not show definite evidence that injection of autologous myoblast beads improves sphincter function, we found that the dog model was suitable and reliable for studying the effects of a potential treatment modality for fecal incontinence.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3616275 | PMC |
http://dx.doi.org/10.4174/jkss.2013.84.4.216 | DOI Listing |
J Biomed Mater Res B Appl Biomater
August 2025
Department of Biomedical Engineering, New Jersey Institute of Technology, Newark, New Jersey, USA.
Volumetric muscle loss (VML) is an injury which leads to debilitating loss of functionality of a muscle. Autologous tissue grafts are used as a standard treatment; however, these grafts often result in complications. Current scaffolds are limited in their ability to restore functionality of the injured muscle, which may be due to lack of cell recruitment to the scaffold and/or lack of sufficient myofiber formation.
View Article and Find Full Text PDFCardiol J
January 2025
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Tech Coloproctol
April 2025
Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd., Weston, FL, 33331, USA.
Background: Since anal fistulas can be challenging to treat; numerous innovative treatments have been proposed, including stem cell therapy. This systematic review aimed to assess pooled rates of fistula healing and adverse events associated with stem cell treatment.
Methods: In this PRISMA-compliant systematic review we searched PubMed and Scopus for observational and randomized studies reporting outcomes of stem cell treatment for anal fistulas.
J Physiol
April 2025
Washington University in St. Louis, St. Louis, Missouri, USA.
Rotator cuff tears are the most common upper extremity orthopaedic injury, causing degenerative changes within the bone, tendon, joint capsule, bursa and muscle. These degenerative changes are linked to poor rehabilitative and surgical outcomes, which has launched investigations into co-therapeutic biologics. Specifically, mesenchymal stem cells (MSCs) have shown promise in mitigating degenerative changes in animal models of rotator cuff tears, but reports of their impact on clinical outcomes remain mixed.
View Article and Find Full Text PDFCytotherapy
June 2025
Office of Cellular and Tissue-based Product, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
In Japan, the Act on Securing Quality, Efficacy, and Safety of Products including Pharmaceuticals and Medical Devices (PMD Act) provides the option for an expedited approval scheme, conditional and time limited, for regenerative medical products only. In March 2024, the Guidance for Conditional and Time-Limited Approval for Regenerative Medical Products and the Development of Subsequent Efficacy Evaluation Plan was established by the Ministry of Health, Labor and Welfare (MHLW). This document is the first guidance on the approval scheme, providing information such as specific examples of the scope of this scheme as well as an indication of what should be considered in the post-marketing approval condition assessment.
View Article and Find Full Text PDF